Suppr超能文献

[肝脏病学中免疫抑制治疗的适应证]

[Indications for immunosuppressive therapy in hepatology].

作者信息

Husa P, Chalupa P

机构信息

Klinika nemocí infekcních FN, Brno.

出版信息

Vnitr Lek. 1998 Nov;44(11):665-70.

Abstract

Immunosuppressive, and in particular corticosteroid therapy, has held its firm place in hepatology for many years. With the development of knowledge on the etiology of liver diseases however the spectrum of diseases where this treatment is administered changes. The authors pay attention in particular to autoimmune hepatitis where the indication for immunosuppressive treatment is beyond doubt. They deal also with viral hepatitis, alcoholic hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis where views on the administration of corticosteroids or immunosuppressive drugs are not uniform. In viral hepatitis administration of corticosteroids is nowadays considered contraindicated as it increases the danger of virus replication and the associated higher risk of a protracted course or development of chronicity. In the contemporary literature the view predominates that corticosteroids reduce the mortality in patients with severe alcoholic hepatitis. In some patients with primary biliary cirrhosis and primary sclerosing cholangitis addition of corticosteroids can improve the inadequate effect of monotherapy with ursodeoxycholic acid. The authors emphasize the necessity of individual evaluation of every single patient before selecting optimal treatment.

摘要

免疫抑制治疗,尤其是皮质类固醇疗法,多年来在肝病学领域一直占据着稳固的地位。然而,随着对肝脏疾病病因认识的发展,接受这种治疗的疾病谱也在发生变化。作者特别关注自身免疫性肝炎,在这种疾病中免疫抑制治疗的指征毫无疑问。他们还探讨了病毒性肝炎、酒精性肝炎、原发性胆汁性肝硬化和原发性硬化性胆管炎,在这些疾病中,关于皮质类固醇或免疫抑制药物的使用观点并不统一。在病毒性肝炎中,如今皮质类固醇的使用被认为是禁忌的,因为它会增加病毒复制的风险以及随之而来的病程延长或发展为慢性的更高风险。当代文献中占主导地位的观点是,皮质类固醇可降低重症酒精性肝炎患者的死亡率。在一些原发性胆汁性肝硬化和原发性硬化性胆管炎患者中,添加皮质类固醇可以改善熊去氧胆酸单一疗法效果不佳的情况。作者强调在选择最佳治疗方法之前,对每一位患者进行个体评估的必要性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验